- Home
- REGN vs COP Comparison
REGN vs COP Comparison
Compare REGN & COP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- COP
- Stock Information
- Founded
- REGN 1988
- COP 1917
- Country
- REGN United States
- COP United States
- Employees
- REGN N/A
- COP N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- COP Integrated oil Companies
- Sector
- REGN Health Care
- COP Energy
- Exchange
- REGN Nasdaq
- COP Nasdaq
- Market Cap
- REGN 110.0B
- COP 122.2B
- IPO Year
- REGN 1991
- COP N/A
- Fundamental
- Price
- REGN $743.35
- COP $113.42
- Analyst Decision
- REGN Buy
- COP Buy
- Analyst Count
- REGN 24
- COP 17
- Target Price
- REGN $1,110.63
- COP $137.38
- AVG Volume (30 Days)
- REGN 837.3K
- COP 5.3M
- Earning Date
- REGN 10-31-2024
- COP 10-31-2024
- Dividend Yield
- REGN N/A
- COP 2.75%
- EPS Growth
- REGN 15.31
- COP N/A
- EPS
- REGN 40.43
- COP 8.44
- Revenue
- REGN $13,847,100,000.00
- COP $56,924,000,000.00
- Revenue This Year
- REGN $10.13
- COP N/A
- Revenue Next Year
- REGN $4.00
- COP $9.85
- P/E Ratio
- REGN $18.39
- COP $13.44
- Revenue Growth
- REGN 5.72
- COP N/A
- 52 Week Low
- REGN $736.01
- COP $101.30
- 52 Week High
- REGN $1,211.20
- COP $135.18
- Technical
- Relative Strength Index (RSI)
- REGN 13.08
- COP 60.25
- Support Level
- REGN $813.53
- COP $112.25
- Resistance Level
- REGN $834.42
- COP $114.46
- Average True Range (ATR)
- REGN 19.56
- COP 2.08
- MACD
- REGN -3.19
- COP 0.42
- Stochastic Oscillator
- REGN 5.83
- COP 82.31
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
About COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.